A cluster randomized trial of interferon ß-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19)

Carolina Iturriaga, Nat Eiffler, Rad Aniba, Rym Ben-Othman, Guillermo Perez-Mateluna, Jessica K V Meyer, Eleanor N Fish, Tobias R Kollmann, Nicolas Severino, Stephen Stick, Arturo Borzutzky, Cecilia Perret, José A Castro-Rodriguez, Diego Garcia-Huidobro, Carolina Iturriaga, Nat Eiffler, Rad Aniba, Rym Ben-Othman, Guillermo Perez-Mateluna, Jessica K V Meyer, Eleanor N Fish, Tobias R Kollmann, Nicolas Severino, Stephen Stick, Arturo Borzutzky, Cecilia Perret, José A Castro-Rodriguez, Diego Garcia-Huidobro

Abstract

Background: SARS-CoV-2 infection rapidly spreads in populations due to the high rates of community transmission. Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19). Herein we provide a protocol for a cluster randomized trial that will examine the effectiveness of treatment with interferon (IFN) ß-1a compared to standard of care in limiting the transmission of SARS-CoV-2. Co-primary objectives are to determine whether IFN therapy reduces (a) the proportion of infected cases shedding SARS-CoV-2 at day 11 post randomization and (b) the incidence of transmission of SARS-CoV-2 infection from index cases to treatment-eligible household post-exposure contacts at day 11 after randomization. Secondary objectives include assessing the impact of IFN treatment on duration of viral clearance, hospitalizations and fatalities, and evaluating the safety of IFN treatment.

Methods: Three hundred and ten households, each including an index case with a recent COVID-19 diagnosis and at least one asymptomatic treatment-eligible household contact, will be randomized to receive 3 doses of 125 μg IFN ß-1a by subcutaneous administration (days 1, 6, and 11), or standard of care. All participants will be followed until day 29.

Discussion: The results from this trial will identify whether IFN ß treatment of mild or moderate COVID-19 cases accelerates viral clearance and prevents disease progression and whether IFN ß treatment of post-exposure contacts of COVID-19 cases reduces transmission of infection.

Trial registration: This trial is registered at ClinicalTrials.gov NCT04552379; date of registration September 17, 2020.

Keywords: COVID; COVID-19; Coronavirus; Interferon; Prevention; Protocol; Transmission.

Conflict of interest statement

Authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Diagram of ConCorD-19 study
Fig. 2
Fig. 2
Household and participant eligibility

References

    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534. doi: 10.1016/S1473-3099(20)30120-1.
    1. Engman ML. SARS outbreak and lessons learned. J Insur Med. 2002;34(2):83–85.
    1. Middle East respiratory syndrome coronavirus (MERS-CoV): World Health Organization. Webpage. World Health Organisation; 2020 March 11 2019. Contract No.: April 6, 2021.
    1. Almeshari MA, Alobaidi NY, Al Asmri M, Alhuthail E, Alshehri Z, Alenezi F, et al. P61 Mechanical ventilation utilization in COVID-19: a systematic review and meta-analysis. Thorax. 2021;76:A121.
    1. Reese H, Iuliano AD, Patel NN, Garg S, Kim L, Silk BJ, et al. Estimated incidence of COVID-19 illness and hospitalization—United States, February–September, 2020. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1780.
    1. World Health Organization. Contact tracing in the context of COVID-19. 2021. . Accessed 1 Feb 2021.
    1. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971. doi: 10.1056/NEJMc2001468.
    1. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-M, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) Int J Infect Dis. 2020;94:154–155. doi: 10.1016/j.ijid.2020.03.020.
    1. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
    1. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol. 2019;43:101300. doi: 10.1016/j.smim.2019.101300.
    1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702. doi: 10.1542/peds.2020-0702.
    1. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222–3228. doi: 10.1001/jama.290.24.3222.
    1. Zhou Q, Macarthur M, He X, Wei X, Zarin P, Hanna B, et al. Interferon-α2b treatment for COVID-19 is associated with improvements in lung abnormalities. Viruses. 2020;13(1):44. doi: 10.3390/v13010044.
    1. Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, Wang Z-H, Tebbutt SJ, Kollmann TR, Fish EN. Interferon-α2b treatment for COVID-19. Frontiers Immunol. 2020;11:1061. doi: 10.3389/fimmu.2020.01061.
    1. Chilean National Institute of Statistics. Chile Population and Housing Census 2017. Santiago, Chile; 2017. .
    1. World Bank. Life expectancy at birth, total (years). The World Bank; 2018. .
    1. Cambero F. Chile records first confirmed case of coronavirus: health ministry. Reuters. 2020. .
    1. Chilean Ministry of Health. Reporte COVID-19: 28% de los casos nuevos se detecta por Búsqueda Activa de Casos. Santiago, Chile: Minesterio de Salud; 2020. .
    1. Lee AH, Shannon CP, Amenyogbe N, Bennike TB, Diray-Arce J, Idoko OT, Gill EE, et al. Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. Nat Commun. 2019;10(1):1–14. doi: 10.1038/s41467-018-07882-8.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. World Health Organization. Corona Virus Disease (COVID-19) Situation Report 50. World Health Organization; 2020. . Accessed 28 Apr 2021.
    1. The Lancet COVID-19 Commission Task Force on Public Health Measures to Suppress the Pandemic. SARS-CoV-2 variants: the need for urgent public health action beyond vaccines; 2021. .

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere